Updated Results from CART-ddBCMA in R/R MM; Could Gilead Take an Interest in the ARC-SparX Platform? Arcellx Meets Clinical Milestones; ASH 2022 Arcellx Investor Event

On Sunday, December 11, Arcellx held an ASH investor event (presentation) highlighting updated clinical data from CART-ddBCMA’s (autologous BCMA CAR-T) Ph1 trial in patients with r/r MM. Moreover, management provided further details on their recently signed collaboration with Gilead (Kite). Below, Celltelligence provides insights on CART-ddBCMA’s potential best-in-class profile while discussing how Gilead’s collaboration could impact the MM space in the long-term.

About The Author

The Celltelligence Team

Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.


You’ll be able to access the full article from your Celltelligence Library after signing up.